Ranolazine Mediated Premature Ventricular Contraction Reduction in Ischemic Heart Disease

Trial Profile

Ranolazine Mediated Premature Ventricular Contraction Reduction in Ischemic Heart Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Ranolazine
  • Indications Myocardial ischaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2016 Planned End Date changed from 1 Dec 2015 to 1 Sep 2017.
    • 01 Sep 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2017.
    • 18 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top